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Abstract
There is increasing appreciation that injured or stressed cells release molecules endowed with the ability to modulate
dendritic cell maturation. The role of these molecules is thought to be that of alerting the body of an impending danger, and
initiate and shape the subsequent immune response. Nucleotides are perfectly suited for this task as they are easily released
upon damage of the cell membrane, rapidly diffuse in the extracellular environment and ligate specific plasma membrane
receptors expressed by dendritic cells and other mononuclear phagocytes. A better knowledge of the modulation of dendritic
cell responses by extracellular nucleotides may provide novel routes to enhance the immune response and increase the
efficacy of vaccination.
Abbreviations: ssRNA –single strand RNA; TLR–toll-like receptors
Introduction
One of the fundamental tenets in immunology is that our
body reacts against foreign (non-self) antigens. Antigenic
molecules, that signal invasion by pathogenic microrgan-
isms, or simply the presence of cells that carry a foreign
genome (as in transplants) are initally sensed by first
line defense immune cells (such as the dendritic cells, DCs,
the prototypic antigen presenting cells, APCs) that initiate
inflammation and the native and adaptive immune re-
sponses [1]. Albeit generally accepted and largely validat-
ed by countless experimental and clinical findings, the
theory that we exclusively or mainly react to non-self mol-
ecules is unable to explain a number of observations that
have bothered immunologists for many years. As pointed
out by Matzinger [2], why we do not react against proteins
that are synthesized late in the life and therefore are not
exposed to lymphocytes during maturation of the immune
system? Or, why do we all harbour auto-reactive B and T
cells, and yet autoimmune diseases are rare? Or, why are
some tissues easier to transplant than others? Over the last
years, the view has emerged that we do not react to non-
self (Fforeign_) molecules but rather to molecules that cause
damage to our tissues. In other words, our body reacts to
Fdanger_ rather than to Fstranger_ [3]. While it is clear that
the Fdanger hypothesis_ does not rule out but rather
complements non-self recognition in immunity, it is also
clear that this novel way to look at the very first phases of
the immune response gives some powerful weapons for the
interpretation of many key events in immunity and
inflammation.
Every physician and every pathologist knows well that
the strongest stimulus for inflammation is tissue damage, to
such an extent that cell injury is thought to be the common
event whereby conditions as different as cancer, chemical
irritants, UV light, closed traumas or biological agents
triggerinflammation[4]. The pro-inflammatory (Fflogistic_)
activity of tissue trauma was long thought to reside in the
release of normally segregated intracellular molecules that
once exteriorized into the extracellular environment would
have the ability to switch on quiescent immune cells. Not
surprisingly, it is well known that necrotic cells are more
likely than apoptotic cells to initiate inflammation [5].
However, the identity of these intracellular molecules has
been ill defined for many years, and the pathways leading
to stimulation of native and adaptive immunity were purely
hypothetical. The merit of the Fdanger signal_ hypothesis as
put forward by Matzinger lays in the description of the
basic features of a danger signal and in the identification of
their role in the initiation of inflammation and in the
modulation of DCs [6]. We will see that extracellular
nucleotides have all the essential features of a Fdanger
signal_, and in fact they may be a type of primordial signal
of tissue distress ubiquitous in the biological world.
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Danger signals: What are they?
According to the current generally accepted definition, we
may define a danger signal as something that is released by
injured or dying cells, is perceived as a sign of tissue
distress, and is endowed with the ability to stimulate DCs
and induce their differentiation [6]. Danger signals can be
endogenous (originating from the host’s cells) or exoge-
nous (released into the body by invading pathogens).
Danger signals can also be generated by tissue destruction
or activation of classical inflammatory pathways [7, 8].
Endogenous danger signals can further be classified into
constitutive or inducible. A key feature of the constitutive
danger signals is their ability to stimulate the release of the
inducible ones. Constitutive danger signals are normally
segregated inside all cells and, so far as they are intracel-
lular, they have no stimulatory activity on the immune
system. Several intracellular constituents are candidates to
this role (see Table 1), among which are extracellular
nucleotides.
A danger signal must be in the first place a good
extracellular messenger because, in case of tissue damage,
it must efficiently travel across the intercellular space to
alert nearby cells. Ideally, any good extracellular messen-
ger should have the following features:
1. It should be easily and quickly generated in the
extracellular space. This would require the presence of
a large pool of intracellular molecules.
2. Under resting conditions its concentration should be
close to zero to allow a high signal-to-noise ratio upon
release. Maintenance of a large pool and a low steady-
state value of messenger molecules is an essential fea-
ture of signalling in biological systems because it allows
a rapid, many-fold change in messenger concentration.
3. It should be highly mobile in the pericellular aqueous
environment, therefore small and hydrophilic molecules
are better suited to this task.
4. It should be recognized by specific receptors expressed
by immune cells.
5. It should be easy to destroy once it reaches the extra-
cellular space. This ensures a quick termination of the
response once the causative agent is removed.
Extracellular nucleotides fulfill all these pre-requisites
as:
1. They are present at a high concentration intracellularly
(ATP 5-10 mM, UTP 0.5Y1 mM), and are quickly re-
leased following cell death, damage, or even simple
plasma membrane stretching. The mechanism by which
ATP can be released in the absence of overt cell damage
is unclear: it is well documented that some cell types
(e.g. platelets [9], neurons [10] or epithelia [11]) secrete
ATP most likely by exocytosis of nucleotide-laden
vesicles. Evidence mostly based on inhibitor studies
suggests that channels or transporters might also par-
ticipate in ATP release (see [12] for recent review).
More controversial is the evidence that pro-inflamma-
tory factors may to drive non-lytic ATP release from
immune cells [13Y16].
2. The extracellular ATP concentration under resting con-
ditions is very low, in the 1Y10 nM range. Paradox-
ically, before the purinergic signalling hypothesis
became accepted, this was taken as evidence against
the role of ATP as an extracellular messenger. On the
contrary, a very low resting level is a fundamental fea-
ture of any messenger, danger signals included.
3. ATP is a small solute (molecular mass 650 Da) bearing
from two to four negative charges, depending on the pH
and the Ca
2+ and Mg
2+ concentration. Thus, it is highly
diffusible in the extracellular aqueous milieu.
4. As of now 15 receptors for extracellular nucleotides
have been identified [17]. The widely differing range of
nucleotide specificity and affinity makes this receptor
family very flexible and efficient in translating infor-
mation delivered by the ligands.
5. All cells express plasma membrane ecto-nucleotidases
that quickly hydrolyze extracellular nucleoside tri-, di-
and mono-phosphates [18]. Interestingly, these enzymes
by generating nucleoside diphosphates from triphos-
phates (e.g. ADP from ATP, or UDP from UTP) and
thus additional ligands also modulate activation of P2
receptors with different specificities.
Are extracellular nucleotides released at sites
of tissue damage?
This may sound as a very naive question. We all believe
that an acutely injured cell will release all its ATP content,
as can be clearly shown in the test tube when a cell
suspension (or a cell monolayer in a Petri dish) is lysed
with a detergent or by freezeYthawing, and the ATP
concentration in the supernatant is measured by the usual
luciferinYluciferase assay. However, in vivo measurements
that document an increase in the extracellular ATP
concentration at sites of inflammation or tissue damage
are few. An early in vivo report by Forrester [19] suggested
that cell membrane stretching can cause ATP secretion.
This author showed that the ATP concentration in the
venous effluent from human exercising muscle increased
from 20 to about 200 pmol/ml, mainly due to release from
Table 1. Intracellular molecules candidates for the role of constitutive
danger signals.
Ligand (danger signal) Receptor (danger sensor)
Heat shock proteins
(HSP60, HSP70, HSP90)
CD91, TLR4, TLR4/TLR2, LOX-1
Uric acid crystals ?
DNA TLR9
ssRNA TLR3, TLR7, TLR8
Nucleotides P2Y1,2,4,6,11, P2X4,7
Sugar metabolites
(UDPglucose)
P2Y14
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vessel injury show that the free ATP concentration in the
blood can rise up to 20 mM from a basal level of 10Y20 nM
[20]. The origin of this ATP is identified as the damaged
vessel wall cells (endothelium and muscle cells), platelets
and other circulating blood cells. Platelets are without
doubt an important source of ATP since they store near
molar amounts of this nucleotide inside their dense
granules. It is worth pointing out that, although nucleotide
release from platelets is generally viewed in the context of
clot formation, we should not forget that platelets are also
one of the most important sources of inflammatory me-
diators, thus ATP release from activated platelets is
certainly proof for ATP release during inflammation.
Implications for a typical inflammatory lesion in which
platelets have a key role, such as the atheromatous plaque,
could be far reaching [21].
A widely held opinion is that the main source of ATP
release in the setting of trauma is the damaged cells. While
this is very likely to occur, a recent study by Nedergaard
and co-workers has documented that shortly (10 min) after
the trauma the main site of ATP release is not the
traumatized region itself, but rather the perilesional area
[22]. It appears that cells that surround the traumatized
tissue are driven into an activated state that persists for
several hours after the injury. Quite interestingly, blockade
of the P2X7 receptor subtype, a main mediator of the pro-
inflammatory effects of ATP, decreased tissue injury and
enhanced functional recovery after the insult. This finding
lends further support to the view that ATP might be one of
the most important early pro-inflammatory signals released
at injury sites. The view that local accumulation of ATP
(and ADP) might have a long lasting action is further
supported by the observation that in mice lacking the main
Langerhans cell ecto-ATPase (CD39) local irritants cause
nucleotide release and an exacerbated skin inflammation
[23]. Furthermore, local accumulation of nucleotides also
affects the outcome of contact dermatitis caused by topical
administrations of allergens. This again concurs to support
the view that nucleotide release at site of injury or inflam-
mation can have far reaching effects on immunomodulation.
Do nucleotides activate DCs?
As summarized above, the main distinguishing feature of a
danger signal resides in its ability to activate DCs and drive
their differentiation. DCs are the most efficient APCs for
activation of naı ¨ve T cells [24]. Thus, they are the key ele-
ments in the initiation of primary immune response. DCs
reside in the tissues as immature cells, but when activated
by a variety of extracellular agents (pathogens, cytokines,
neurotransmitters), they mature and migrate to the lym-
phonodes where they stimulate T cell differentiation [1,
24]. DCs have become a focus of attention as a possible
target for extracellular nucleotides only very recently,
nonetheless a wealth of data is already available on the
pattern of P2R expression and the functional responses
associated with their stimulation.
DCs express both P2YRs (P2Y1, P2Y2, P2Y4, P2Y6,
P2Y11 and P2Y14)a n dP 2 X R s( P 2 X 1,P 2 X 4,P 2 X 7)
[25Y30]. Acute, transient, stimulation with ATP or UTP
causes many of the responses typically associated with
P2Y or P2X activation (phosphatidyl inositol breakdown,
release of Ca
2+ from intracellular stores, Ca
2+ influx across
the plasma membrane, and even opening of the P2X7 large
conductance pore if a high ATP concentration is used).
Nucleotide effects on DC responses are dramatically
different whether they are due to exposure to chronic low
(10Y250 mM) or acute high (500 mM to millimolar) con-
centrations. Chronic stimulation triggers a process of DC
maturation that enhances their ability to stimulate Th2
lymphocytes and thus initiate a type 2 immune response. In
the presence of ATP the expression of typical markers
(CD54, CD80, CD83, CD86) of DC maturation is in-
creased, furthermore endocytic activity is reduced and the
capacity to promote proliferation of allogeneic lympho-
cytes enhanced. ATP alone, at variance with classical
maturation factors, does not induce cytokine or chemokine
secretion [31, 32]. However, in the presence of maturating
factors (e.g. bacterial endotoxin, LPS, or CD40L), ATP
strongly distorts the pattern of cytokine produced. LPS or
CD40L-dependent release of IL-1b, IL-1a, TNF-a, IL-6
and IL-12 is inhibited, while release of the IL-1 receptor
antagonist and IL-10 is not affected. As a result, when co-
cultured with naı ¨ve Th lymphocytes these DCs promote a
Th2 polarization, witnessed by the typical pattern of
cytokines produced by the stimulated lymphocytes (low
interferon +, high IL-4, IL-5 and IL-10). The pattern of
chemokine receptors expressed by DCs is also strongly
modified by chronic exposure to low ATP concentrations.
Receptors for inflammatory chemokines such as CC
chemokine receptor 5 (CCR5) are down modulated while
those for lymphoid chemokines such as CXC chemokine
receptor 4 (CXC4R) and CCR7 are upregulated [33]. This
has far reaching consequences in recirculation of dendritic
cells from tissues to the lymphonodes, and from blood into
tissues. In fact, following exposure to pathogens or tissue
damage, resident immature DCs respond to inflammatory
chemokines to become activated, concentrate in the in-
flamed tissue, take up antigens, mature and migrate to the
regional lymphonodes. During maturation DCs upmodulate
receptors for lymphoid chemokines, that allow lympho-
node localization and enhance their ability to interact with
naı ¨ve T cells. ATP priming also affects the pattern of
chemokines secreted by DCs: constitutive production of
the lymphoid chemokine CCL22 is increased, while the
LPS-stimulated secretion of the inflammatory chemokines
CXCL10 and CCL5 is inhibited [33]. This shift in chemo-
kine release favours recruitment of Th2 rather than Th1
lymphocytes. Thus, in summary chronic exposure to low
ATP concentrations has a strong modulatory activity on
DC maturation by enhancing their ability to localize in the
lymphonodes and to initiate a type 2 rather than a type 1
immune response (see Figure 1 for a schematic rendering).
The P2Rs responsible for such an immunomodulatory
effect have not been conclusively identified, but conver-
gent data point to P2Y11 as the most likely candidate [29]
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[31]). However, at this very preliminary stage we cannot
exclude that other P2YRs or P2XRs may also participate in
DC maturation. Involvement of different P2Rs in DC
maturation is also suggested by a recent work of Schnurr
and co-workers [34] showing that ATP-primed DCs have a
differential ability to activate naive or memory T cells.
This further stresses the complexity and the potential
relevance of purinergic signalling in the manipulation of
DC responses.
We are faced with a completely different scenario when
DCs are acutely challenged with high ATP doses in
association with a bacterial pathogen. In this case secretion
of pro-inflammatory cytokines is potently stimulated and,
if exposure to ATP is not discontinued, cell death occurs
[27, 35]. This pro-inflammatory activity is non dissimilar
from that elicited by ATP in many other mononuclear
phagocytes [36, 37]. The IL-1b-releasing activity of ATP is
particularly striking: in cells primed with LPS the addition
of this nucleotide causes an explosive acceleration of pro-
IL-1b processing and the consequent exteriorization of the
mature cytokine embedded into plasma membrane-derived
microvesicles [38]. It is of interest that ATP is unable to
drive IL-1b release in phagocytes that have not been
previously primed with LPS, thus reinforcing ATP’s role as
danger signal that acts in concert with bacterial pathogens
to initiate inflammation. On the other hand, the inability of
LPS to drive IL-1b secretion in the absence of ATP further
supports the view that bacterial factors are incomplete
stimuli in the absence of endogenously-released danger
signals.
Nucleotides may shape the immune response also by
having a differential effect on DC recruitment. Idzko and
co-workers have shown that immature but not mature DCs
chemotact in response to a nucleotide gradient [39]. This
would allow recruitment of immature DCs to the ATP-rich
inflammatory site, but would not prevent migration of
mature DCs to regional lymph nodes. Many other immune
cells, such as mast cells, macrophages and microglia, are
sensitive to the chemotactic activity of ATP, UTP or ADP,
thus reinforcing the role of nucleotides as powerful
activators of inflammation [40Y42]. As of now there are
no reports of an in vivo modulatory activity of extracellular
ATP on dendritic cell function, but the observations
reported in mice deleted of the main ecto-ATPase of
immune cells (CD39) point in this direction [23].
Conclusion
The danger model for the initiation of the immune response
is enjoying increasing appreciation. Although overenthusi-
Figure 1. Cell damage caused by physical trauma or pathogens causes an initial wave of ATP release (red) from injured cells. This first wave of ATP
release diffuses through the pericellular space and activates adjacent cells (e.g. epithelial cells, macrophages, fibroblasts). P2 receptors expressed on the
plasma membrane of the bystander cells will be activated and trigger the release of several bioactive agents, among which ATP itself (ATP-induced ATP
release, dark blue). Accumulation of ATP into the extracellular milieu will prime Langerhans/dendritic cells (DC) and modify their responses to bacterial
endotoxin (LPS) or T lymphocyte-derived CD40 ligand (CD40L). The combined action of these agents drives DC maturation and the secretion of
cytokines and chemokines.
208 F. Di Virgilioastic generalizations should be avoided, we think that it
provides a useful guidance to comprehension of the initial
phases of inflammation. In this context, nucleotides are an
outstanding example of how an intracellular molecule, with
no obvious links to immunity, can modulate the immune
response if released extracellularly.
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